Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3Observational 1Expanded_access 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 32Colorectal Neoplasms 8Brain Neoplasms 7Stomach Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Meningeal Neoplasms 3HER2-positive Breast Cancer 3Rectal Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Carcinomatosis 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Diseases 1

Interventions

Trastuzumab 30pertuzumab 16Docetaxel 16pyrotinib 11Paclitaxel 7Carboplatin 5Capecitabine 5Ado-Trastuzumab Emtansine 4tucatinib 3trastuzumab deruxtecan 2atezolizumab 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2pegfilgrastim 1palbociclib 1neratinib 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Goserelin 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × HER2-positive Breast Cancer × tucatinib × Clear all
NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting
650 enrolled
Breast

HER2-positive Breast Cancer

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Seagen Inc.

Phase 3 Active not recruiting
466 enrolled 17 charts
Breast

HER2-positive Breast Cancer

NCT05955170 2025-03-27

TUC-TOC

Institut Curie

Phase 2 Recruiting
66 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡